Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director · Chairman and CEO | October 07, 2026 | October 08, 2026 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 479,803 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Exercise / conversion · Acquired 4,991 · Balance 484,794 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Row 2 · 2026-10-07 · Sale · Disposed 4,991 · Balance 479,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. |
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $146.34 · Expires 2026-11-21 | Direct | 4,993 |
Reported balance
After 2026-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-07 · Exercise / conversion · Disposed 4,991 · Balance 4,993 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3: Represents date options first become exercisable. Options vest 1/3 per year |
| ResMed Common StockSEC Table I · non-derivative | IndirectLisette and Michael Farrell Family Trust | 2,090 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,090 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 per year
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 20,073.731 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 417.363 · Balance 20,073.731 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2022 Filed Jul 18, 2022 17:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-019401 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,265 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 17:31 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $224.94 | $1,276,517.48 |
DisclosureSEC source: 0001127602-22-019401 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.45 to $225.95. The price reported above reflects the weighted average sale price. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 17:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-019401 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 297.477 | $0.00 Strike: $105.05 | $0.00 |
DisclosureSEC source: 0001062993-22-015940 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,147.228 Underlying: Common Stock · 297.477 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 19:47 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-017597 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,940 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 19:47 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $202.54 | $1,149,409.96 |
DisclosureSEC source: 0001127602-22-017597 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $199.47 to $206.01. The price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 19:47 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-017597 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 16, 2022 Filed May 17, 2022 17:20 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-014711 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,615 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 16, 2022 Filed May 17, 2022 17:20 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $196.61 | $1,115,744.73 |
DisclosureSEC source: 0001127602-22-014711 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $195.10 to $198.04. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 30.8872 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 16, 2022 Filed May 17, 2022 17:20 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-014711 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 13, 2022 Filed May 17, 2022 21:33 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,129.158 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-012809 · form4.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,812.158 Underlying: Common Stock · 1,129.158 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Also reflects the adjustments that occurred as of March 1, 2022 in connection with the spinoff of ZimVie Inc. In connection with the spinoff, each then outstanding Restricted Stock Unit was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit. Read SEC document |
| May 13, 2022 Filed May 17, 2022 21:33 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $115.13 | $0.00 |
DisclosureSEC source: 0001062993-22-012809 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,849.751 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 19.183 phantom stock units accrued on April 29, 2022 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:34 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-012221 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,290 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:34 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $232.41 | $1,318,946.61 |
DisclosureSEC source: 0001127602-22-012221 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $231.15 to $234.52. The price reported above reflects the weighted average sale price. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:34 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-012221 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:16 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 242.568 | $0.00 Strike: $128.83 | $0.00 |
DisclosureSEC source: 0001062993-22-009409 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,330.568 Underlying: Common Stock · 242.568 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 19.410 phantom stock units accrued on January 31, 2022 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F5 · balance_after: Holdings reflect the adjustments that occurred as of March 1, 2022 in connection with the Company's spinoff of Zimvie Inc. In connection with the spinoff, each outstanding phantom stock unit was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 19:24 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-009461 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,965 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 19:24 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $242.37 | $1,375,421.94 |
DisclosureSEC source: 0001127602-22-009461 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $238.87 to $244.98. The price reported above reflects the weighted average sale price. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 19:24 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-009461 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 23:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-005395 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,640 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 23:31 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $234.06 | $1,328,270.64 |
DisclosureSEC source: 0001127602-22-005395 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $232.67 to $235.27. The price reported above reflects the weighted average sale price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 23:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-005395 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:37 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-001718 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,315 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:37 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $241.94 | $1,372,990.77 |
DisclosureSEC source: 0001127602-22-001718 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $239.63 to $246.44. The price reported above reflects the weighted average sale price. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:37 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-001718 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:56 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 244.083 | $0.00 Strike: $128.03 | $0.00 |
DisclosureSEC source: 0001062993-22-000354 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,766.969 Underlying: Common Stock · 244.083 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 16.139 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:23 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-031221 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,990 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:23 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $255.53 | $1,450,141.26 |
DisclosureSEC source: 0001127602-21-031221 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $253.51 to 259.63. The price reported above reflects the weighted average sale price. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:23 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-21-031221 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 00:32 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 3,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029967 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette & Michael Farrell Family Foundation Disclosed balance after: 3,880 F2 · kind: Gift of shares transferred from The Lisette and Michael Farrell Family Trust, Mr. Farrell retains dispositive power over the gifted shares. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 00:32 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 3,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029967 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 5,090 F1 · kind: Gift of shares transferred to The Lisette and Michael Farrell Foundation, Mr. Farrell retains dispositive power over remaining shares. Read SEC document |
| November 19, 2021 Filed Nov 18, 2021 22:44 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 44,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F4 · kind: Gift of shares to the Farrell Legacy Trust. Mr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:44 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 4,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,479 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 22:44 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 42,210 | $254.81 | $10,755,530.10 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,010 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:44 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 71,262 | $254.81 | $18,158,270.22 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,220 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 18:18 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 8,748 | $259.47 | $2,269,843.56 |
DisclosureSEC source: 0001127602-21-029088 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,958 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted for dates 11/14/2018, 11/21/2019 and 11/19/2020. F2 · balance_after: Includes 94.5633 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:10 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 210.622 | $0.00 Strike: $148.37 | $0.00 |
DisclosureSEC source: 0001062993-21-009197 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,506.747 Underlying: Common Stock · 210.622 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 13.325 phantom stock units accrued on July 31, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 15:57 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 18,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024088 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,611 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. F2 · balance_after: Includes 33.4591 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:39 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 194.184 | $0.00 Strike: $160.93 | $0.00 |
DisclosureSEC source: 0001062993-21-006279 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,282.8 Underlying: Common Stock · 194.184 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| May 14, 2021 Filed May 18, 2021 23:03 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 779.05 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-004823 · form4.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,453.057 Underlying: Common Stock · 779.05 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 14, 2021 Filed May 18, 2021 23:03 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $166.87 | $0.00 |
DisclosureSEC source: 0001062993-21-004823 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,088.616 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 11.383 phantom stock units accrued on April 30, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:42 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 169.785 | $0.00 Strike: $161.97 | $0.00 |
DisclosureSEC source: 0001062993-21-003334 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577.233 Underlying: Common Stock · 169.785 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 12.776 phantom stock units accrued on January 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:53 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 7,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002062 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,160 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:49 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 179.891 | $0.00 Strike: $152.87 | $0.00 |
DisclosureSEC source: 0001062993-21-000109 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,394.672 Underlying: Common Stock · 179.891 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 14.859 phantom stock units accrued on October 30, 2020 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:48 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 49,776 | $214.74 | $10,688,898.24 |
DisclosureSEC source: 0001127602-20-029558 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,146 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:48 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 89,238 | $214.74 | $19,162,968.12 |
DisclosureSEC source: 0001127602-20-029558 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,922 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:06 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,221 | $212.11 | $471,096.31 |
DisclosureSEC source: 0001127602-20-029033 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,684 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:06 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,973 | $212.11 | $630,603.03 |
DisclosureSEC source: 0001127602-20-029033 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,905 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:06 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,417 | $212.11 | $724,779.87 |
DisclosureSEC source: 0001127602-20-029033 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,878 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 121.68 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:36 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 202.563 | $0.00 Strike: $135.76 | $0.00 |
DisclosureSEC source: 0001062993-20-004775 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,199.922 Underlying: Common Stock · 202.563 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 13.729 phantom stock units accrued on July 31, 2020 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.